Physician profile
Theodore C Bailey
NPI 1275785842
$2,665.95
in general payments reported to CMS, 2019-2025
12 companies · $827 in 2025
The $827 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.76 · 2021: $22.06 · 2022: $202 · 2023: $785 · 2024: $788 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $930.14 | 2021-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $637.91 | 2023-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $281.35 | 2019-2025 | Zerbaxa, Dificid, Pifeltro |
| Abbvie INC. | $259.18 | 2023-2025 | Dalvance, Avycaz |
| Insmed, INC. | $189.54 | 2023-2025 | Arikayce, Brinsupri |
| Janssen Biotech, INC. | $104.17 | 2022-2023 | Symtuza |
| Dynavax Technologies Corporation | $74.14 | 2022-2024 | Heplisav-B |
| Aimmune Therapeutics, INC. | $68.71 | 2023-2024 | |
| Paratek Pharmaceuticals, INC. | $53.85 | 2025 | Nuzyra |
| Astellas Pharma US INC | $25.66 | 2025 | Cresemba |
| Cepheid | $22.77 | 2024 | Xpert C. Difficile/Epi |
| Pfizer INC. | $18.53 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.